Celecoxib May Benefit Benign Prostatic Hyperplasia
Nocturia and prostate symptom scores significantly improve following treatment with a cyclooxygenase-2 inhibitor
THURSDAY, Oct. 2 (HealthDay News) -- Celecoxib is a novel treatment option for patients with benign prostatic hyperplasia (BPH) experiencing refractory nocturia, according to a report in the October issue of Urology.
Siavash Falahatkar, M.D., of the University of Medical Sciences in Rasht, Islamic Republic of Iran, and colleagues performed a prospective, randomized, double-blind, placebo-controlled study examining the efficacy of celecoxib for the treatment of 80 patients with BPH and nocturia. Patients with an International Prostate Symptom Score greater than 8 and complaints of two or more voids nightly were randomized to receive 100 mg celecoxib or placebo for one month.
In the celecoxib group, there was a significant decline in International Prostate Symptom Scores (18.2 to 15.5) and average nocturia (5.17 episodes to 2.5 episodes per night), the researchers report. In the control group, nocturia (5.3 episodes to 5.1 episodes per night) and International Prostate Symptom Scores also declined (18.4 to 18.0), but the differences were not significant, the report indicates. Peak urinary flow rates were not significantly different between the two groups, or between baseline and after one month of treatment in the celecoxib group.
"In the present study, nocturia either improved or disappeared in 82.5 percent of patients after celecoxib treatment compared with 22.5 percent in the placebo group," the authors comment. "This dramatic response is better than any known treatment, including alpha-blockers and, even, surgery."